Drug intelligence / Profile preview

paltimatrectinib

Development stage: Phase 1
Lead developer: Biohaven
Modality: Small Molecules
Administration: Oral

Overview

Paltimatrectinib (also known as PBI-200) is an orally bioavailable, brain-penetrant, potent, and selective pan-tropomyosin-related-kinase (TRK) inhibitor developed by Pyramid Biosciences. It is designed to overcome resistance mutations observed with first-generation TRK inhibitors. Paltimatrectinib is being investigated for its potential antineoplastic activity in NTRK fusion-positive solid tumors, including primary and metastatic brain tumors. The FDA has granted Orphan Drug Designation to PBI-200 for this indication.

Targets

NTRK1 (Tropomyosin-related receptor kinase A)NTRK3 (Tropomyosin receptor kinase C)NTRK2 (Tropomyosin-related kinase receptor type B)

Beyond the preview

Go deeper on paltimatrectinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on paltimatrectinib.

Explore the full profile